Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05392582
Other study ID # 153158
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 1, 2023
Est. completion date January 1, 2028

Study information

Verified date March 2024
Source University of Utah
Contact Micah Drummond, PhD
Phone 801-213-2737
Email micah.drummond@hsc.utah.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an observational study enrolling healthy individuals aged 18-35 and 65y and older to determine the health of immune cells in the blood and how these cells create inflammation and effect health as we age. It is hoped that once the nature of this relationship has been discovered we can more effectively design therapies to reduce this inflammation. The enrollment goal is 40 participants. The study will occur over the course of 1 month which will include a screening visit and a second visit where the participants will undergo an oral glucose tolerance test, blood draws and leg strength & exercise tests.


Description:

We will recruit healthy, non-obese (<30kg/m2 BMI) younger (N=20; 18-35y) and older (N=20; >65y) male and female participants (as determined by sample size calculation) in the Salt Lake City area. 1. VISIT 1 (Screening, visit duration: 1 hour): Once the participant is identified, they will be scheduled for a screening visit at the CTSI (421 Wakara Way) to see if they meet incl/excl criteria and to sign an informed consent document. As part of the visit, Upon arrival, we will gather basic health information such as height, weight, blood pressure, and heart rate. - Participant will undergo the following procedures: a blood screening (30ml of blood collected) - For older cohort: The clinical frailty scale (CFS) and Mini-Cog© cognitive assessment 2. VISIT 2 (visit duration: 3 hours) Following a 10h fast, participants will arrive in the morning. Upon arrival, we may gather basic health information from the participant such as height, weight, blood pressure, and heart rate. The procedures to take place at this visit are as follows: - 120 mL serum blood sample collection. Samples will be used to identify the immune cell populations in the blood, regulators of these immune cells and how these cells function. - Oral glucose tolerance test (OGTT)- participants will be asked to complete a test to determine their blood sugar levels. We will ask them to drink a sugary liquid (glucola) and then rest quietly while we measure changes in their blood sugar levels. We will draw 20 ml of blood during this test (~1 tablespoon). OGTT will take approximately 2hours. - Leg strength tests at the SMERF facility. Isometric strength will be assessed in both legs with a maximal voluntary isometric contraction effort developed by the knee extensors (quadriceps) on a isokinetic dynamometer. For lower extremity extension power testing a Nottingham power rig will be used. Total time for these tests will take 45 minutes.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date January 1, 2028
Est. primary completion date January 1, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age between 18 - 35y; 65y and older 2. BMI: <30 kg/m2 3. Ability to sign informed consent 4. For older participant group: Clinical Frailty Scale score < 3 and Mini-Cog score > 3 5. Good general medical health, ambulatory and in independent living setting Exclusion Criteria: - History of cardiovascular disease (e.g., CHF, CAD, MI, CVA) - History of endocrine or metabolic disease such as hypo/hyperthyroidism and diabetes (Treated hypo/hyperthyroid for at least 6 months will be permitted) - History of kidney disease or failure (CKD > stage 4) - History of vascular disease - Uncontrolled hypertension - Elevated systolic pressure >150 or a diastolic blood pressure > 100 - Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma - Chronic systemic corticosteroid use (= 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular/topical/inhaled therapeutic or physiologic doses of corticosteroids will be permitted) - Chronic anti-inflammatory medication use (= 2 weeks) within 4 weeks of enrollment - Chronic inflammatory conditions (e.g., Rheumatoid Arthritis, Crohn's, fibromyalgia, lupus, colitis) HIV, Hepatitis B and C - History of stroke with motor disability - A recent history (<12 months) of GI bleed - History of liver disease or AST/ALT 2 times above the normal limit - History of respiratory disease (acute upper respiratory infection, history of chronic lung disease) - Current smokers or current tobacco use - Current pregnancy as determined by positive pregnancy test - Any staff members who report directly to the principal investigators.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States The University of Utah Salt Lake City Utah

Sponsors (1)

Lead Sponsor Collaborator
University of Utah

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Inflammation IL-6 levels Determined in older adults and in younger adults at a single visit (baseline).
See also
  Status Clinical Trial Phase
Completed NCT03625427 - Effect of Palmitoleic Acid on C-reactive Protein N/A
Recruiting NCT05068557 - EPICO: (Study for the Pro-resolution of Chronic Inflammation in Obesity. Original Acronym From Spanish) N/A
Not yet recruiting NCT05050812 - The Grounded Brain: How Sleeping Grounded Affects Memory and Perceptions N/A
Recruiting NCT02395354 - Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease N/A
Completed NCT01686204 - Reduction of Obesity-Associated Intestinal Inflammation by Low-Fat Dairy Yogurt N/A
Completed NCT02963662 - Impact of Gut Hormones and Inflammatory Adipokines in Obese Patients Underwent Bariatric Surgery N/A
Recruiting NCT05304689 - Analysis of the Relationship Between the Quantitative Index of Cytokines in the Oral Fluid and Inflammation N/A
Recruiting NCT06401785 - To Evaluate the Efficacy of Oral Molecular Hydrogen Supplement in Patients With Chronic Diseases Phase 2
Completed NCT05209867 - Single-cell CBD Biomarkers of Inflammation Reduction in People Living With HIV Phase 4
Terminated NCT00211471 - Treatment of Rubeosis Iridis With Open-Label Anecortave Acetate Sterile Suspension ( 15 mg.). Phase 2
Recruiting NCT04447144 - Nutritional Habits, and Coronavirus Disease 2019 (COVID-19) Outcome
Not yet recruiting NCT06444763 - Effect of Maolactin™ FMR on Exercise Recovery, Inflammation and Muscle Comfort in an Otherwise Healthy Population Phase 3
Terminated NCT02661295 - A Study of Ferric Citrate to Improve Inflammation and Lipid Levels Phase 4
Completed NCT02506192 - Gulf War Illness Inflammation Reduction Trial Phase 2
Completed NCT04023318 - The BMI Project (Body, Mind, Inflammation) N/A
Recruiting NCT04971408 - Impact of Passive Heat on Metabolic, Inflammatory and Vascular Health in Persons With Spinal Cord Injury N/A
Enrolling by invitation NCT02520206 - Adenosylmethionine Metabolism in Human Inflammation N/A
Recruiting NCT04979130 - Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus (SIB) Phase 4
Completed NCT04636723 - Neuroinflammation in Chronic Systemic Symptoms (CSS)
Completed NCT02084381 - PERCI- Medium Cut Off (MCO) N/A